ampelopsin has been researched along with Aortic Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Feng, L; Li, Z; Ou, C; Que, D; Wei, J; Yan, J; Yang, P; Zhang, X; Zhong, X | 1 |
| Chen, X; Liu, TT; Tang, K; Xu, XL; Zeng, Y; Zhang, W | 1 |
2 other study(ies) available for ampelopsin and Aortic Diseases
| Article | Year |
|---|---|
Dihydromyricetin ameliorates vascular calcification in chronic kidney disease by targeting AKT signaling.
Topics: Animals; Aorta; Aortic Diseases; Cells, Cultured; Disease Models, Animal; Flavonols; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Osteogenesis; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Signal Transduction; Vascular Calcification | 2021 |
Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta; Aortic Diseases; Atherosclerosis; Cytokines; Diet, High-Fat; Disease Models, Animal; Flavonols; Foam Cells; Genetic Predisposition to Disease; Human Umbilical Vein Endothelial Cells; Humans; Inflammation Mediators; Lipoproteins, LDL; Liver; Male; Mice; Mice, Knockout; Oxidative Stress; Phenotype; Plaque, Atherosclerotic; RAW 264.7 Cells; Receptors, LDL | 2017 |